Table 3.
Patient background according to the PPS with a cutoff value of 22 mg/dL.
| Prealbumin Prognostic Score (Prealbumin Cutoff Value: 22 mg/dL) |
PPS Score 0 N = 3421 |
PPS Score 1 N = 984 |
PPS Score 2 N = 258 |
p Value |
|---|---|---|---|---|
| Age (years), Median (IQR) | 64.0 (56.0, 71.0) | 68.0 (57.0, 76.0) | 70.0 (64.0, 78.0) | <0.001 |
| Sex | <0.001 | |||
| Male | 2377 (69.5%) | 458 (46.5%) | 159 (61.6%) | |
| Female | 1044 (30.5%) | 526 (53.5%) | 99 (38.4%) | |
| Body mass index, Median (IQR) | 22.7 (20.7, 24.7) | 21.6 (19.4, 24.3) | 21.5 (19.8, 24.1) | <0.001 |
| Comorbidity | ||||
| Chronic kidney disease | 449 (13.1%) | 138 (14.0%) | 51 (19.8%) | 0.011 |
| Diabetes | 257 (7.5%) | 120 (12.2%) | 37 (14.3%) | <0.001 |
| CRP (mg/dL), Median (IQR) | 0.08 (0.03, 0.10) | 0.10 (0.05, 0.30) | 1.30 (0.74, 2.28) | <0.001 |
| Prealbumin (mg/dL), Median (IQR) | 28.1 (25.2, 31.5) | 20.3 (18.1, 21.6) | 17.1 (14.2, 19.8) | <0.001 |
| >22.0 | 3421 (100.0%) | 175 (17.8%) | 0 (0%) | |
| 15.0–22.0 | 0 (0%) | 740 (75.2%) | 171 (66.3%) | <0.001 |
| <15.0 | 0 (0%) | 69 (7.0%) | 87 (33.7%) | |
| Clinical stage | ||||
| I | 2599 (76.0%) | 630 (64.0%) | 98 (38.0%) | <0.001 |
| II | 406 (11.9%) | 139 (14.1%) | 46 (17.8%) | |
| III | 397 (11.6%) | 199 (20.2%) | 104 (40.3%) | |
| IVA | 19 (0.6%) | 16 (1.6%) | 10 (3.9%) | |
| Surgical approach | ||||
| Laparoscopic surgery | 2198 (64.3%) | 496 (50.4%) | 70 (27.1%) | <0.001 |
| Open surgery | 1223 (35.7%) | 488 (49.6%) | 188 (72.9%) | |
| Surgical procedure | ||||
| Distal gastrectomy | 1929 (56.4%) | 593 (60.3%) | 153 (59.3%) | <0.001 |
| Total gastrectomy | 679 (19.8%) | 220 (22.4%) | 88 (34.1%) | |
| Proximal gastrectomy | 166 (4.9%) | 33 (3.4%) | 4 (1.6%) | |
| Pylorus-preserving gastrectomy | 647 (18.9%) | 138 (14.0%) | 13 (5.0%) | |
| Lymph node dissection | ||||
| D1+ | 2009 (58.7%) | 491 (49.9%) | 73 (28.3%) | <0.001 |
| D2 | 1412 (41.3%) | 493 (50.1%) | 185 (71.7%) | |
| Serosal invasion | 477 (13.9%) | 266 (27.0%) | 130 (50.4%) | <0.001 |
| Lymph node metastasis | ||||
| N1 | 433 (12.7%) | 137 (13.9%) | 55 (21.3%) | <0.001 |
| N2 | 289 (8.4%) | 108 (11.0%) | 42 (16.3%) | |
| N3 | 236 (6.9%) | 125 (12.7%) | 42 (16.3%) | |
| Pathological stage | ||||
| I | 2350 (68.7%) | 571 (58.0%) | 92 (35.7%) | <0.001 |
| II | 582 (17.0%) | 186 (18.9%) | 63 (24.4%) | |
| III | 489 (14.3%) | 227 (23.1%) | 103 (39.9%) | |
| Histological type | ||||
| Differentiated | 1507 (44.1%) | 431 (43.8%) | 120 (46.5%) | 0.724 |
| Undifferentiated | 1914 (55.9%) | 553 (56.2%) | 138 (53.5%) | |
| Postoperative complications | ||||
| Overall complications | 682 (19.9%) | 194 (19.7%) | 61 (23.6%) | 0.339 |
| Severe complications | 233 (6.8%) | 67 (6.8%) | 25 (9.7%) | 0.210 |
| Adjuvant chemotherapy | 630 (18.4%) | 208 (21.1%) | 93 (36.0%) | <0.001 |